title: Steroid-induced diabetes in rheumatologic patients.
abstract: Glucocorticoids are widely used to suppress inflammation - especially in the acute phase - in several inflammatory and autoimmune rheumatologic diseases. Despite their efficacy, their long-term use or at high doses is associated with numerous well-characterised side effects. Hyperglycaemia or frank diabetes is one of the most common, as its prevalence is estimated between 10-20%. Its pathophysiology is mainly due to increased insulin resistance. In this review, we provide a practical guide on how to monitor patients who are started on glucocorticoids, and how to detect and manage steroid-induced hyperglycaemia or diabetes.
authors.affiliation: Rheumatology-Clinical Immunology Unit, Institute for Biomedical Research of the Academy of Athens, Athens, Greece. angelopoulos_theodoros@yahoo.gr.
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Angelopoulos
authors.forename: Nikolaos K
authors.initials: NK
authors.lastname: Tentolouris
authors.forename: George K
authors.initials: GK
authors.lastname: Bertsias
authors.forename: Dimitrios T
authors.initials: DT
authors.lastname: Boumpas
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003920:Diabetes Mellitus / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007333:Insulin Resistance; D011379:Prognosis; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers; D001786:Blood Glucose; D005938:Glucocorticoids